A patient who loses a large amount of total weight but also loses too much muscle may feel weaker, colder, less energetic, or more prone to weight regain
Heddle, R., Fone, D., Dent, J
10.1038/cddis.2017.28 Summary Keywords GLP-1, oral delivery, vagal afferents, diabetes, obesity, peptide Citation New RRC, Bogus M, Travers GN, Hahn U, Vaiceliunaite A, Burnet M, Wang JH and Wen H (2024) Glucagon-like peptide-1 receptor agonists for treatment of diabetes and obesity: advantage of oral delivery
A provider-guided approach combining genetic insights, baseline biomarker assessment, and your individual health history enables more precise conversations about whether .25mg dosing aligns with your metabolic profile and treatment goals
Sometimes people are not hungry in the morning or for much of the day on these medications